**Core Concept**
In managing acute coronary syndromes, particularly in the setting of ST-elevation myocardial infarction (STEMI), timely administration of thrombolytic therapy is crucial to restore coronary blood flow and minimize cardiac damage. However, this treatment is contraindicated in certain situations where the risk of bleeding outweighs the benefits.

**Why the Correct Answer is Right**
Thrombolytic therapy is not recommended in patients with a history of bleeding disorders, recent bleeding, or those who are at high risk of bleeding, such as those with a history of stroke or surgery within the past 3 months. Additionally, thrombolytic therapy is contraindicated in patients with a high risk of cardiac rupture, such as those with a history of recent cardiac surgery or those with a large anterior STEMI. In this elderly male patient with a 24-hour history of chest pain and sweating, the ECG likely shows ST-elevation indicative of STEMI, but the use of thrombolytic therapy would be contraindicated due to the risk of bleeding.

**Why Each Wrong Option is Incorrect**
**Option A:** Aspirin is given in managing patients with acute coronary syndromes as an antiplatelet agent to prevent further clot formation.
**Option B:** Statin is given to manage patients with acute coronary syndromes to lower cholesterol levels and reduce inflammation in the arterial wall.
**Option D:** Morphine is given to manage patients with acute coronary syndromes to relieve chest pain and reduce anxiety.

**Clinical Pearl / High-Yield Fact**
In managing acute coronary syndromes, it is essential to carefully assess the patient's risk-benefit profile before administering thrombolytic therapy, as the risk of bleeding can be significant and even life-threatening.

**✓ Correct Answer: C. Thrombolytic therapy**